Jazz wins FDA nod for cancer therapy developed with BeOne, Zymeworks
Jazz secured FDA approval for its cancer treatment co-developed with BeOne and Zymeworks.
Along with the favorable news of FDA approval, the stock price is positioned just below the 20-day resistance line ($265.05) and maintains a stable, gradual upward alignment above the support line ($240.63), making a purchase worth considering.
If the stock price remains stable above the support line ($240.63) in a gentle upward alignment trend and rebounds, we will sell at the take-profit target price of $265.05. Conversely, if the price declines and breaks below the stop-loss price of $240.63, we will execute a stop-loss.
At the time of entry, the technical indicators show that the RSI(14) is at 40.3, a modest level just before reaching oversold territory; moving averages are in a bullish alignment (short-term above long-term); trading volume is at 0.53x the 20-day average; and the 7-day volatility/return rate stands at +3.5%.
An entry was attempted based on the clear positive catalyst of an FDA cancer treatment approval, with the stock price positioned just below the 20-day resistance line ($265.05) and expected to maintain an upward alignment (bullish moving average arrangement) above the support line ($240.63). However, the actual outcome resulted in a -10.8% return, breaching the stop-loss level of $240.63 and receiving a FAILED rating. This confirmed that despite the RSI (14) at 40.3 and trading volume being somewhat low at 0.53 times the 20-day average at the time of entry, relying on the increasing trend of theme-related news and approval news was insufficient to fend off downward pressure.
This failure taught us that even with strong favorable news and thematic momentum, a lack of supply and demand support—such as trading volume falling below the 20-day moving average—can leave a stock more vulnerable to downside volatility. Going forward, we will strictly adhere to mechanical stop-loss responses in the event of a support line breach, while more conservatively verifying and reflecting the concurrence of trading volume and technical indicators as our entry criteria.